BD Solutions for Efficient Management of HAIs

Healthcare-associated infections (HAIs) are a major cause of morbidity and mortality around the world. An estimated 6 million healthcare-associated infections occur each year across the U.S., Europe and Japan alone. Beyond the human toll, HAIs poses an enormous financial burden to healthcare systems worldwide. BD is committed to applying its expertise, resources and technologies toward the prevention of healthcare-associated infections worldwide. Helping to prevent HAIs perfectly aligns with BD's core purpose of "helping all people live healthy lives".

BD Diagnostics offers you a comprehensive range of assays (Screening/Diagnostic; Molecular/ Chromogenic/ Conventional) to identify HAI causing organisms in the most efficient way corresponding to your unique and individual setting.

For the latest information on BD's strategy concerning HAIs, please sign up at BD HAIs Web site www.bd.com/HAIs.

Learn more about...

	First Healthcare-Associated Infection Assay on the BD MAX™ System Launches in Europe. »
The BD Innova™ Advanced Specimen Processor - Experience Efficiency »
	BD Completes Acquisition of HandyLab, Inc. »
Introducing the BD MAX™ - Fully Automated Bench-top System for Molecular Diagnostics »
	BD Adds Surveillance Capability to Infectious Disease Portfolio » »
	BD GeneOhm™ Cdiff Assay CE Marked and Submitted for FDA Clearance »
	HAI Archive»